314 related articles for article (PubMed ID: 19421832)
1. Renal toxicity of targeted therapies.
Kelly RJ; Billemont B; Rixe O
Target Oncol; 2009 Apr; 4(2):121-33. PubMed ID: 19421832
[TBL] [Abstract][Full Text] [Related]
2. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
Ravaud A; Sire M
Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
[No Abstract] [Full Text] [Related]
3. Adverse effects of anticancer agents that target the VEGF pathway.
Chen HX; Cleck JN
Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
[TBL] [Abstract][Full Text] [Related]
4. [Angiogenesis and renal cell carcinoma].
Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
[TBL] [Abstract][Full Text] [Related]
5. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Coriat R; Ropert S; Mir O; Billemont B; Chaussade S; Massault PP; Blanchet B; Vignaux O; Goldwasser F
Invest New Drugs; 2011 Oct; 29(5):1090-3. PubMed ID: 20524036
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
7. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
Patel TV; Morgan JA; Demetri GD; George S; Maki RG; Quigley M; Humphreys BD
J Natl Cancer Inst; 2008 Feb; 100(4):282-4. PubMed ID: 18270341
[No Abstract] [Full Text] [Related]
8. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Snider KL; Maitland ML
Target Oncol; 2009 Apr; 4(2):67-76. PubMed ID: 19373440
[TBL] [Abstract][Full Text] [Related]
9. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
Wollenberg A; Staehler M; Eames T
Hautarzt; 2010 Aug; 61(8):662-7. PubMed ID: 20631979
[TBL] [Abstract][Full Text] [Related]
10. American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Kibble A; Shumoogam J
IDrugs; 2007 Aug; 10(8):509-12. PubMed ID: 17665319
[No Abstract] [Full Text] [Related]
11. [Vascular and renal effects of anti-angiogenic therapy].
Halimi JM; Azizi M; Bobrie G; Bouché O; Deray G; des Guetz G; Lecomte T; Levy B; Mourad JJ; Nochy D; Oudard S; Rieu P; Sahali D
Nephrol Ther; 2008 Dec; 4(7):602-15. PubMed ID: 19027389
[TBL] [Abstract][Full Text] [Related]
12. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
13. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
[No Abstract] [Full Text] [Related]
14. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
Vaklavas C; Lenihan D; Kurzrock R; Tsimberidou AM
Oncologist; 2010; 15(2):130-41. PubMed ID: 20139170
[TBL] [Abstract][Full Text] [Related]
15. [Oral drugs inhibiting the VEGF pathway].
Ropert S; Mir O; Armand JP
Bull Cancer; 2007 Jul; 94 Spec No():S180-90. PubMed ID: 17846003
[TBL] [Abstract][Full Text] [Related]
16. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
English BC; Price DK; Figg WD
Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
[No Abstract] [Full Text] [Related]
17. Newly approved therapies for RCC and their effect on the standard of care.
Figlin RA
Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
[No Abstract] [Full Text] [Related]
18. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
Chen MH
Curr Cardiol Rep; 2009 May; 11(3):167-74. PubMed ID: 19379636
[TBL] [Abstract][Full Text] [Related]
19. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F
Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549
[No Abstract] [Full Text] [Related]
20. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Hiles JJ; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
